Journal of Clinical Medicine
Cure8 research brief
Why This Matters
People with UC on tofacitinib may experience asymptomatic reactivation of HSV or VZV detectable by PCR, which could be relevant for infection monitoring and vaccination discussions. The study did not find clear links to worse disease activity, but was small, so uncertainty remains.
Who Should Pay Attention
Adult patients with ulcerative colitis on or considering JAK inhibitors (tofacitinib), their clinicians, and researchers studying infection risks of immunomodulatory therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study suggests that oral PCR-detected reactivation of Herpesviridae can occur without symptoms in some UC patients on tofacitinib. It did not find clear links between viral detection and worse clinical activity or fecal calprotectin, but was small and not designed to rule out clinically meaningful risks.
The findings are drawn from the study abstract and cohort summary provided by the journal article. If you take tofacitinib or care for someone who does: discuss herpes virus risk and vaccination history with your clinician; clinicians may consider vigilance for symptomatic reactivation and adhere to local guidance on zoster vaccination and monitoring.
The study does not provide evidence to change treatment decisions on its own.
Keep In Mind
Structured content depth: abstract — the classification and notes are based on the journal article abstract and provided study summary. The cohort was small (27 patients, 24 with saliva PCR) and not powered to detect associations between viral detection and clinical outcomes; absence of symptomatic zoster in this cohort does not exclude risk in larger populations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Clinical Medicine
PublisherMDPI AG
AuthorsSivan Harnik, Naama Lang, Shiran Yehezkel +11 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 14, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Pfizer, award 64184455
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prospective Evaluation of Ustekinumab Dose Intensification in Inflammatory Bowel Diseases.
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group.
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti-tumor necrosis factor alpha therapy in children.
This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...